Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:ALT NASDAQ:INZY NASDAQ:KALA NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.82-4.7%$3.36$1.24▼$4.08$747.70M1.024.16 million shs11.79 million shsALTAltimmune$3.78-2.3%$3.76$2.90▼$11.16$333.61M0.183.64 million shs4.43 million shsINZYInozyme Pharma$4.00$3.99$0.72▼$6.24$258.25M2.27960,267 shsN/AKALAKALA BIO$19.63+12.0%$9.85$2.92▼$20.60$137.80M-1.81113,307 shs369,708 shsVKTXViking Therapeutics$25.40-2.5%$30.57$18.92▼$81.73$2.86B0.734.84 million shs7.27 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+5.71%-1.00%-2.63%-19.57%+119.26%ALTAltimmune+8.40%+4.88%+6.91%-45.09%-47.91%INZYInozyme Pharma0.00%0.00%0.00%+0.25%-31.15%KALAKALA BIO+0.34%+3.12%+108.94%+333.91%+202.24%VKTXViking Therapeutics+12.78%+1.17%+6.90%+0.12%-59.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.82-4.7%$3.36$1.24▼$4.08$747.70M1.024.16 million shs11.79 million shsALTAltimmune$3.78-2.3%$3.76$2.90▼$11.16$333.61M0.183.64 million shs4.43 million shsINZYInozyme Pharma$4.00$3.99$0.72▼$6.24$258.25M2.27960,267 shsN/AKALAKALA BIO$19.63+12.0%$9.85$2.92▼$20.60$137.80M-1.81113,307 shs369,708 shsVKTXViking Therapeutics$25.40-2.5%$30.57$18.92▼$81.73$2.86B0.734.84 million shs7.27 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+5.71%-1.00%-2.63%-19.57%+119.26%ALTAltimmune+8.40%+4.88%+6.91%-45.09%-47.91%INZYInozyme Pharma0.00%0.00%0.00%+0.25%-31.15%KALAKALA BIO+0.34%+3.12%+108.94%+333.91%+202.24%VKTXViking Therapeutics+12.78%+1.17%+6.90%+0.12%-59.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.00Buy$6.75139.36% UpsideALTAltimmune 2.57Moderate Buy$17.40360.32% UpsideINZYInozyme Pharma 2.38Hold$11.14178.57% UpsideKALAKALA BIO 3.20Buy$27.5040.09% UpsideVKTXViking Therapeutics 3.00Buy$87.50244.49% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, VKTX, INZY, KALA, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $35.009/11/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $33.009/8/2025KALAKALA BIOMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$30.009/3/2025KALAKALA BIOLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/19/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.008/13/2025AKBAAkebia TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.007/24/2025VKTXViking TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$125.00 ➝ $122.007/24/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $38.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M4.67N/AN/A($0.23) per share-12.26ALTAltimmune$20K16,680.57N/AN/A$1.74 per share2.17INZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/AKALAKALA BIO$3.89M35.42N/AN/A$2.02 per share9.72VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)ALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)INZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%N/AKALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest AKBA, VKTX, INZY, KALA, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84ALTAltimmune0.0920.4420.44INZYInozyme Pharma0.652.192.19KALAKALA BIO3.192.102.10VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ALTAltimmune78.05%INZYInozyme Pharma88.30%KALAKALA BIO24.61%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ALTAltimmune4.40%INZYInozyme Pharma12.18%KALAKALA BIO8.32%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.14 million257.19 millionOptionableALTAltimmune5088.26 million84.37 millionOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableKALAKALA BIO307.02 million6.44 millionNot OptionableVKTXViking Therapeutics20112.45 million107.84 millionOptionableAKBA, VKTX, INZY, KALA, and ALT HeadlinesRecent News About These CompaniesViking Therapeutics (NASDAQ:VKTX) Trading Up 10.6% - Should You Buy?1 hour ago | marketbeat.comPrediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 MonthsSeptember 19 at 4:40 AM | fool.comViking Therapeutics, Inc. $VKTX Shares Sold by Harbor Capital Advisors Inc.September 18 at 3:58 AM | marketbeat.comViking Therapeutics, Inc. (VKTX): A Bull Case TheorySeptember 18 at 2:12 AM | finance.yahoo.comBiotech Breakouts: 3 Stocks With Massive Upside Potential (VKTX)...September 17 at 6:22 PM | marketbeat.comWesbanco Bank Inc. Has $1.38 Million Holdings in Viking Therapeutics, Inc. $VKTXSeptember 17 at 3:55 AM | marketbeat.comViking Therapeutics, Inc. $VKTX Position Reduced by Voya Investment Management LLCSeptember 17 at 3:27 AM | marketbeat.comViking Therapeutics, Inc. (VKTX): A Bull Case Theory September 16 at 2:31 PM | insidermonkey.comAMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?September 16 at 2:01 PM | zacks.comViking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to KnowSeptember 15, 2025 | zacks.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Buy" by BrokeragesSeptember 15, 2025 | marketbeat.comWoodline Partners LP Acquires 207,784 Shares of Viking Therapeutics, Inc. $VKTXSeptember 14, 2025 | marketbeat.comWealth Management Associates Inc. Purchases Shares of 9,975 Viking Therapeutics, Inc. $VKTXSeptember 13, 2025 | marketbeat.comAlliancebernstein L.P. Decreases Position in Viking Therapeutics, Inc. $VKTXSeptember 12, 2025 | marketbeat.comViking Therapeutics (VKTX): Reassessing Valuation After Clinical Trial Setback and Weak EarningsSeptember 11, 2025 | finance.yahoo.comWhere Does VKTX Stock Stand After the Obesity Pill Setback?September 11, 2025 | zacks.comWall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?September 9, 2025 | zacks.com5 Stocks Poised to DOUBLE Your Money by 2027September 9, 2025 | 247wallst.comViking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to NoteSeptember 8, 2025 | zacks.comViking Therapeutics, Inc. $VKTX Shares Acquired by Curi RMB Capital LLCSeptember 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025AKBA, VKTX, INZY, KALA, and ALT Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.82 -0.14 (-4.73%) Closing price 04:00 PM EasternExtended Trading$2.84 +0.02 (+0.71%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Altimmune NASDAQ:ALT$3.78 -0.09 (-2.33%) Closing price 04:00 PM EasternExtended Trading$3.80 +0.02 (+0.53%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Inozyme Pharma NASDAQ:INZYInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.KALA BIO NASDAQ:KALA$19.63 +2.10 (+11.98%) Closing price 04:00 PM EasternExtended Trading$19.56 -0.07 (-0.38%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Viking Therapeutics NASDAQ:VKTX$25.40 -0.64 (-2.46%) Closing price 04:00 PM EasternExtended Trading$25.59 +0.19 (+0.75%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive NIO's New Dawn: Why Wall Street's Bullish Turn Signals a Comeback Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
